{
  "code": "PHA",
  "name": "Pharmacy/Drug Stores",
  "totalSpending": 262167944.48000002,
  "totalFilings": 9053,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 26281627.48,
      "filings": 1052
    },
    {
      "year": 2019,
      "income": 29259172,
      "filings": 1134
    },
    {
      "year": 2020,
      "income": 32028000,
      "filings": 1161
    },
    {
      "year": 2021,
      "income": 32870168,
      "filings": 1053
    },
    {
      "year": 2022,
      "income": 36775836,
      "filings": 1159
    },
    {
      "year": 2023,
      "income": 35042955,
      "filings": 1198
    },
    {
      "year": 2024,
      "income": 30310832,
      "filings": 1055
    },
    {
      "year": 2025,
      "income": 39599354,
      "filings": 1241
    }
  ],
  "topClients": [
    {
      "name": "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA",
      "income": 8240000
    },
    {
      "name": "WALGREEN CO.",
      "income": 7120000
    },
    {
      "name": "CVS HEALTH",
      "income": 4995000
    },
    {
      "name": "ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY",
      "income": 4150000
    },
    {
      "name": "PHRMA",
      "income": 3352500
    },
    {
      "name": "VIATRIS INC",
      "income": 3330000
    },
    {
      "name": "CIGNA CORPORATION",
      "income": 3080000
    },
    {
      "name": "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION",
      "income": 3053398
    },
    {
      "name": "GENENTECH, INC.",
      "income": 2930000
    },
    {
      "name": "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)",
      "income": 2895000
    },
    {
      "name": "HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.)",
      "income": 2880000
    },
    {
      "name": "UNITEDHEALTH GROUP, INC.",
      "income": 2870000
    },
    {
      "name": "COMMUNITY ONCOLOGY ALLIANCE",
      "income": 2800000
    },
    {
      "name": "HEALTHCARE DISTRIBUTION ALLIANCE",
      "income": 2760000
    },
    {
      "name": "ELI LILLY AND COMPANY",
      "income": 2680000
    },
    {
      "name": "NATIONAL ASSOCIATION OF CHAIN DRUG STORES",
      "income": 2630000
    },
    {
      "name": "THE CAMPAIGN FOR SUSTAINABLE RX PRICING",
      "income": 2570000
    },
    {
      "name": "NEUROCRINE BIOSCIENCES, INC.",
      "income": 2560000
    },
    {
      "name": "AMERICA'S HEALTH INSURANCE PLANS",
      "income": 2540000
    },
    {
      "name": "TRAVERE THERAPEUTICS",
      "income": 2505000
    },
    {
      "name": "AMERICAN VETERINARY MEDICAL ASSOCIATION",
      "income": 2440000
    },
    {
      "name": "ALKERMES, INC.",
      "income": 2250000
    },
    {
      "name": "PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION",
      "income": 2150000
    },
    {
      "name": "CVS HEALTH INC",
      "income": 2150000
    },
    {
      "name": "ALLIANCE FOR RURAL HOSPITAL ACCESS",
      "income": 2010000
    },
    {
      "name": "DYNAVAX TECHNOLOGIES",
      "income": 2000000
    },
    {
      "name": "SK AMERICAS, INC.",
      "income": 1920000
    },
    {
      "name": "NOVO NORDISK INC.",
      "income": 1890000
    },
    {
      "name": "IQVIA",
      "income": 1880000
    },
    {
      "name": "TEVA PHARMACEUTICALS USA, INC.",
      "income": 1795000
    },
    {
      "name": "ASSOCIATION OF ACCESSIBLE MEDICINES",
      "income": 1730000
    },
    {
      "name": "CENTRIENT PHARMACEUTICALS LLC",
      "income": 1720000
    },
    {
      "name": "ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)",
      "income": 1710000
    },
    {
      "name": "AMERISOURCEBERGEN CORPORATION",
      "income": 1670000
    },
    {
      "name": "CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION)",
      "income": 1620000
    },
    {
      "name": "CHILDREN'S NATIONAL MEDICAL CENTER",
      "income": 1600000
    },
    {
      "name": "BIOTECHNOLOGY INDUSTRY ORGANIZATION",
      "income": 1600000
    },
    {
      "name": "ASTRAZENECA PHARMACEUTICALS LP",
      "income": 1600000
    },
    {
      "name": "340B HEALTH",
      "income": 1583500
    },
    {
      "name": "DR. REDDY'S LABORATORIES, LTD",
      "income": 1545000
    },
    {
      "name": "LILLY USA, LLC",
      "income": 1530000
    },
    {
      "name": "ALLIANCE FOR PHARMACY COMPOUNDING",
      "income": 1520000
    },
    {
      "name": "BLUE SHIELD OF CALIFORNIA",
      "income": 1500000
    },
    {
      "name": "AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY)",
      "income": 1460000
    },
    {
      "name": "AMGEN USA INC.",
      "income": 1440000
    },
    {
      "name": "ALVOGEN, PHARMA US, INC.",
      "income": 1440000
    },
    {
      "name": "NATIONAL ASSOCIATION OF SPECIALTY PHARMACY",
      "income": 1440000
    },
    {
      "name": "BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY)",
      "income": 1435000
    },
    {
      "name": "SANOFI U.S. SERVICES, INC.",
      "income": 1410000
    },
    {
      "name": "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION",
      "income": 1400000
    }
  ],
  "topFirms": [
    {
      "name": "MEHLMAN CONSULTING, INC.",
      "income": 14580000
    },
    {
      "name": "TODD STRATEGY GROUP",
      "income": 11630000
    },
    {
      "name": "RUBICON ADVISORS, LLC",
      "income": 8966174
    },
    {
      "name": "KOUNTOUPES DENHAM CARR & REID, LLC",
      "income": 8900000
    },
    {
      "name": "BGR GOVERNMENT AFFAIRS",
      "income": 8770000
    },
    {
      "name": "MARSHALL & POPP, LLC",
      "income": 7420000
    },
    {
      "name": "TARPLIN, DOWNS & YOUNG, LLC",
      "income": 6870000
    },
    {
      "name": "FOLEY & LARDNER LLP",
      "income": 6765000
    },
    {
      "name": "BROWNSTEIN HYATT FARBER SCHRECK, LLP",
      "income": 5780000
    },
    {
      "name": "FORBES-TATE",
      "income": 5650000
    },
    {
      "name": "FARRAGUT PARTNERS LLP",
      "income": 4860000
    },
    {
      "name": "AKIN GUMP STRAUSS HAUER & FELD",
      "income": 4220000
    },
    {
      "name": "INVARIANT LLC",
      "income": 3610000
    },
    {
      "name": "RICCHETTI INCORPORATED",
      "income": 3600000
    },
    {
      "name": "PENN AVENUE PARTNERS",
      "income": 3520000
    },
    {
      "name": "RED+BLUE STRATEGIES",
      "income": 3310000
    },
    {
      "name": "THE KPM GROUP DC LLC",
      "income": 3270000
    },
    {
      "name": "BALLARD PARTNERS",
      "income": 3250000
    },
    {
      "name": "ACG ADVOCACY",
      "income": 2950000
    },
    {
      "name": "FIERCE GOVERNMENT RELATIONS",
      "income": 2580000
    },
    {
      "name": "ALSTON & BIRD LLP",
      "income": 2560000
    },
    {
      "name": "BUCHANAN INGERSOLL & ROONEY PC",
      "income": 2540000
    },
    {
      "name": "MCDERMOTT+ LLC",
      "income": 2490000
    },
    {
      "name": "ARTEMIS POLICY GROUP LLC",
      "income": 2474000
    },
    {
      "name": "BOCKORNY GROUP, INC.",
      "income": 2470000
    },
    {
      "name": "AMERICAN VETERINARY MEDICAL ASSOCIATION",
      "income": 2440000
    },
    {
      "name": "BLUESTONE STRATEGIES, LLC",
      "income": 2390000
    },
    {
      "name": "FEROX STRATEGIES",
      "income": 2390000
    },
    {
      "name": "HANCE SCARBOROUGH",
      "income": 2350000
    },
    {
      "name": "POLARIS GOVERNMENT RELATIONS, LLC",
      "income": 2320000
    }
  ],
  "sampleDescriptions": [
    "Drug shortages and FDA approval.  USTR acceptance.",
    "drug pricing, drug supply chain, opioid abuse epidemic, Medicare Part D",
    "Controlled Substance act improvements. Opioid overdose death reduction. Alprazolam rescheduling.",
    "Federal government relations service, strategy development and implementation relating to companys status of FDA action on NDA for oral testosterone.",
    "Issues related to health insurance and prescription drug pricing.",
    "Time-Temperature Indicators for Pharmaceuticals; and Drug Quality and Security Act",
    "Issues relating to the regulations around drug manufacturing.",
    "Drug FDA Approval: CAM2038",
    "Federal government relations service, strategy development and implementation relating to status of FDAs action with regards to the companys NDA.",
    "Federal government relations service, strategy development and implementation relating to regenerative medicine products.",
    "Education and support for public policies that promote the development, use, coverage and reimbursement of novel, non-opioid pain therapies.",
    "Issues relating to the regulation of PBMs and healthcare.",
    "Medicare/Medicaid drug coverage, opioid addiction policy, S.2456 The CARA 2.0 Act of 2018.",
    "CREATES Act, biosimilars regulation, drug pricing, intellectual property issues related to pharmaceuticals",
    "Implementation of the Drug Quality and Security Act",
    "Biodefense, Biomedical Advanced Research and Development Authority funding, vaccine research, development, manufacturing and marketing, infectious diseases, cancer, PAHPA, Labor-HHS Appropriations bil",
    "Social Security, Healthcare",
    "Addressing the high cost of pharmaceutical drugs",
    "Issues related to the 340B drug discount program",
    "Asthma policies and diagnostic test reimbursement. Drug shortage prevention and abuse-deterrent pseudophedrine."
  ],
  "quarterlyTrend": [
    {
      "quarter": "2018-first_quarter",
      "filings": 238,
      "spending": 8756824.294370074
    },
    {
      "quarter": "2018-fourth_quarter",
      "filings": 278,
      "spending": 10924832.368070818
    },
    {
      "quarter": "2018-second_quarter",
      "filings": 247,
      "spending": 9126512.326472221
    },
    {
      "quarter": "2018-third_quarter",
      "filings": 289,
      "spending": 10105417.323930267
    },
    {
      "quarter": "2019-first_quarter",
      "filings": 282,
      "spending": 11475579.195614029
    },
    {
      "quarter": "2019-fourth_quarter",
      "filings": 291,
      "spending": 11706470.812837454
    },
    {
      "quarter": "2019-second_quarter",
      "filings": 265,
      "spending": 9934859.031522399
    },
    {
      "quarter": "2019-third_quarter",
      "filings": 296,
      "spending": 10244585.10791606
    },
    {
      "quarter": "2020-first_quarter",
      "filings": 270,
      "spending": 11785867.925440742
    },
    {
      "quarter": "2020-fourth_quarter",
      "filings": 307,
      "spending": 12032804.717225991
    },
    {
      "quarter": "2020-second_quarter",
      "filings": 305,
      "spending": 10929540.37715997
    },
    {
      "quarter": "2020-third_quarter",
      "filings": 279,
      "spending": 11170116.092295626
    },
    {
      "quarter": "2021-first_quarter",
      "filings": 228,
      "spending": 10491468.867271649
    },
    {
      "quarter": "2021-fourth_quarter",
      "filings": 283,
      "spending": 12452287.855278207
    },
    {
      "quarter": "2021-second_quarter",
      "filings": 275,
      "spending": 9779641.268237317
    },
    {
      "quarter": "2021-third_quarter",
      "filings": 267,
      "spending": 10206393.267669259
    },
    {
      "quarter": "2022-first_quarter",
      "filings": 276,
      "spending": 12704332.50867945
    },
    {
      "quarter": "2022-fourth_quarter",
      "filings": 298,
      "spending": 13397284.837770892
    },
    {
      "quarter": "2022-second_quarter",
      "filings": 283,
      "spending": 12316267.143277306
    },
    {
      "quarter": "2022-third_quarter",
      "filings": 302,
      "spending": 12751070.754197441
    },
    {
      "quarter": "2023-first_quarter",
      "filings": 302,
      "spending": 18159031.47517507
    },
    {
      "quarter": "2023-fourth_quarter",
      "filings": 295,
      "spending": 17371311.600147076
    },
    {
      "quarter": "2023-second_quarter",
      "filings": 297,
      "spending": 15096202.90853036
    },
    {
      "quarter": "2023-third_quarter",
      "filings": 304,
      "spending": 16939986.210656013
    },
    {
      "quarter": "2024-first_quarter",
      "filings": 236,
      "spending": 15612463.295323752
    },
    {
      "quarter": "2024-fourth_quarter",
      "filings": 277,
      "spending": 15549501.109734705
    },
    {
      "quarter": "2024-second_quarter",
      "filings": 259,
      "spending": 13477274.101877613
    },
    {
      "quarter": "2024-third_quarter",
      "filings": 283,
      "spending": 15056252.748989897
    },
    {
      "quarter": "2025-first_quarter",
      "filings": 251,
      "spending": 15756601.61399712
    },
    {
      "quarter": "2025-fourth_quarter",
      "filings": 334,
      "spending": 17450059.769544177
    },
    {
      "quarter": "2025-second_quarter",
      "filings": 305,
      "spending": 17154219.483644135
    },
    {
      "quarter": "2025-third_quarter",
      "filings": 351,
      "spending": 17135000.558928326
    }
  ],
  "totalEstimatedSpending": 417050061
}